Here's an excerpt from their Web site:
What We Do
Our core mission is to support in every way the development of preventive AIDS vaccines that are not only safe and effective, but also accessible to all people. To that end, IAVI invests the bulk of its resources in the research and clinical assessment of candidate vaccines against strains of HIV that are prevalent in the developing world, where some 95% of new HIV infections occur.
Our scientific team works with more than 40 academic, commercial and government institutions to develop and assess candidate HIV vaccines. Together, our partners and we have so far evaluated six vaccines in early-stage clinical trials conducted in 11 countries across four continents. To do this critical work, we, together with local research institutions, have developed a network of sophisticated laboratories in India and in southern and eastern Africa. Our Human Immunobiology Laboratory in London helps coordinate the work of these labs.
In the arena of vaccine design, we have brought leading HIV researchers together into three scientific consortia–the Neutralizing Antibody Consortium (NAC), the HIV Live-Attenuated Consortium and the Vectors Consortium—to address key obstacles to the development of an effective AIDS vaccine and to generate novel candidates.
In developing countries, we work closely with governmental, community and civic organizations to ensure the transparent and ethical conduct of clinical trials. To that end, we support the staffing and training of Community Advisory Boards, which represent the communities in which clinical trials are conducted and help design trial protocols. We help educate people about vaccine trials and the need for AIDS vaccines. And we help build both the clinical and scientific capacity required to run a long-term program of vaccine trials.
We also analyze and develop policies to promote the involvement of the private sector in AIDS vaccine research and development. And we advocate for policies that will ensure that once an AIDS vaccine is developed, it will be swiftly produced, distributed and made affordable worldwide.